OLD Media News

Bayer buys gene therapy company for $4 bln

Pharma giant Bayer will buy U.S. biotech company Asklepios BioPharmaceutical for $4 billion as it forges deeper into gene therapy.

Ludwig Burger reported the news for Reuters:

Bayer BAYGn.DE agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses.

Germany’s Bayer will pay $2 billion upfront and up to an additional $2 billion in milestone payments contingent on development achievements, it said on Monday.

Nick Paul Taylor from Fierce Biotech wrote:

Asklepios, known as AskBio, is a veteran of the gene therapy space. Jude Samulski, a pioneer of AAV vectors, founded the company in 2001. Since then, AskBio has built out an AAV platform and associated high-yield cell line and worked with Columbus Venture Partners to establish gene therapy manufacturing capacity, a scarce, valuable resource in the booming industry. The manufacturing site is run by Viralgen, the CDMO AskBio set up with Columbus.

The Wall Street Journal’s Ruth Bender noted:

The German company’s biggest pharmaceutical acquisition since its purchase of domestic rival Schering AG in 2006 is also an attempt to tackle one of a series of challenges that has been plaguing the inventor of aspirin, especially since its 2018 acquisition of U.S.-based Monsanto.

The $63 billion Monsanto deal was meant to give the company another big, fast-growing revenue stream besides pharmaceuticals. Instead, it has saddled Bayer with a protracted legal battle over whether Monsanto’s Roundup weedkillers cause cancer—a dispute that has pummeled Bayer’s share price. Bayer says Roundup is safe.

Irina Slav

Recent Posts

CNBC taps Sullivan as “Power Lunch” co-anchor

CNBC senior vice president Dan Colarusso sent out the following on Monday: Before this year comes to…

1 day ago

Business Insider hires Brooks as standards editor

Business Insider editor in chief Jamie Heller sent out the following on Monday: I'm excited to share…

1 day ago

Is this the end of CoinDesk as we know it?

Former CoinDesk editorial staffer Michael McSweeney writes about the recent happenings at the cryptocurrency news site, where…

2 days ago

LinkedIn finance editor Singh departs

Manas Pratap Singh, finance editor for LinkedIn News Europe, has left for a new opportunity…

3 days ago

Washington Post announces start of third newsroom

Washington Post executive editor Matt Murray sent out the following on Friday: Dear All, Over the last…

4 days ago

FT hires Moens to cover competition and tech in Brussels

The Financial Times has hired Barbara Moens to cover competition and tech in Brussels. She will start…

4 days ago